Testosterone in cancer survivors

20 Oct Testosterone in cancer survivors

The Testosterone in Cancer Survivors study is a research study in men, ages 18-54, who have received chemotherapy and/or radiation therapy for their cancer and are now off-treatment and in remission for at least 1 year. The purpose of this study is to evaluate whether testosterone, an important hormone in men, improves fatigue, sexual function, quality of life, muscle mass, muscle strength, and physical activity in cancer survivors who report fatigue and have low testosterone. Fatigue is one of the most common symptoms of cancer treatment and is also very common in cancer survivors, even months to years after the end of their treatment.

If you decide to participate, you will receive a health screening evaluation and blood tests to determine if you qualify for the study. If you are found eligible and agree to enroll in the study, you will be asked to attend 6 to 8 study visits at the Seattle VA hospital over 9 months. At each visit, you will undergo study procedures including: a blood draw, physical exam, questionnaires, physical function tests, body imaging, and general questions about your health. You will also receive testosterone injections or placebo (like water with salt that has no medical effects). Your health will be closely monitored by study clinicians.

Participant Eligibility

-Male
-Between the age of 18 to 54
-Received chemotherapy and/or radiation therapy for your cancer treatment
-Completed active cancer treatment and have been remission for at least one year
-Have not been diagnosed with prostate, breast, or brain cancer
-Have not been treated with testosterone, DHEA, or growth hormone in the past 6 months
-Have not had a stroke, heart attack, or revascularization surgery in the past 3 months
-Have not been diagnosed with bipolar disorder or schizophrenia
-Do not have untreated sleep apnea
-Do not have an immediate family member with a diagnosis of prostate cancer

Contact

Gary Miranda
(206) 277-6143